---
figid: PMC12246557__MCO2-6-e70297-g001
figtitle: Type I, type II, and type III interferon signaling and IFN‐I pathway‐related
  inhibitors
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12246557
filename: MCO2-6-e70297-g001.jpg
figlink: /pmc/articles/PMC12246557/figure/F5/
number: F5
caption: Type I, type II, and type III interferon signaling and IFN‐I pathway‐related
  inhibitors. Type I, type III, and type II interferons activate different typical
  signaling pathways leading to downstream induction of interferon‐sensitive response
  element (ISRE)‐driven and IFN‐γ‐activation site (GAS)‐driven target genes. IFN‐I
  binds the IFNAR receptor complex (composed of IFNAR1 and IFNAR2); type II interferon
  binds the IFNGR receptor complex (IFNGR1 and IFNGR2); and type III interferon binding
  IFNLR receptor complex (composed of INFLR1 and IL‐10Rβ). Binding of interferons
  to specific receptors results in activation of the Janus kinase (JAK)‐signal transducer
  and activator of transcription (STAT) pathway. Transcriptional activation of the
  IFN‐I signaling pathway requires that STAT dimers bind interferon regulatory factors
  (IRFs), that is, IRF9, translocated into the nucleus, where they bind to interferon
  signaling genes (IFGs) promoters on the ISREs or GASs, and binding to these promoter
  elements leads to the transcription of hundreds of IFGs
papertitle: 'Sjögren''s Syndrome: Epidemiology, Classification Criteria, Molecular
  Pathogenesis, Diagnosis, and Treatment'
reftext: Ying Hu, et al. MedComm (2020). 2025 Jul;6(7).
year: '2025'
doi: 10.1002/mco2.70297
journal_title: MedComm
journal_nlm_ta: MedComm (2020)
publisher_name: Wiley
keywords: classification criteria | diagnosis | epidemiology | molecular pathogenesis
  | Sjögren's syndrome | treatment
automl_pathway: 0.9466045
figid_alias: PMC12246557__F5
figtype: Figure
redirect_from: /figures/PMC12246557__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12246557__MCO2-6-e70297-g001.html
  '@type': Dataset
  description: Type I, type II, and type III interferon signaling and IFN‐I pathway‐related
    inhibitors. Type I, type III, and type II interferons activate different typical
    signaling pathways leading to downstream induction of interferon‐sensitive response
    element (ISRE)‐driven and IFN‐γ‐activation site (GAS)‐driven target genes. IFN‐I
    binds the IFNAR receptor complex (composed of IFNAR1 and IFNAR2); type II interferon
    binds the IFNGR receptor complex (IFNGR1 and IFNGR2); and type III interferon
    binding IFNLR receptor complex (composed of INFLR1 and IL‐10Rβ). Binding of interferons
    to specific receptors results in activation of the Janus kinase (JAK)‐signal transducer
    and activator of transcription (STAT) pathway. Transcriptional activation of the
    IFN‐I signaling pathway requires that STAT dimers bind interferon regulatory factors
    (IRFs), that is, IRF9, translocated into the nucleus, where they bind to interferon
    signaling genes (IFGs) promoters on the ISREs or GASs, and binding to these promoter
    elements leads to the transcription of hundreds of IFGs
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IFNK
  - IFNW1
  - IFNA1
  - IFNA2
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA17
  - IFNA21
  - IFNB1
  - HOXC6
  - IFNAR1
  - IFNAR2
  - JAK1
  - TYK2
  - STAT1
  - IRF9
  - STAT2
  - JAK2
  - IFNG
  - Tofacitinib
  - Baricitinib
  - Ruxolitinib
  - Nucleus
---
